sellWeak cluster of 310b5-1 plan
Catriona Yale sold $652k of AKRO
Chief Development Officer at Akero Therapeutics, Inc.. 20,000 shares at an average of $32.60, traded Oct 30, 2024, filed Nov 1, 2024.
Warning score
25Value
$652k
20,000 shares
Holdings after
74,158
-25% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +20Trade size$652k at market
- +10Share of holdings soldSold 25% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-120231, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 30, 2024 | MOption exercise Common Stock10b5-1 | +4,515 | $21.10 | $95k | 78,673 | Nov 1, 2024 |
| Oct 30, 2024 | SOpen-market sale Common Stock10b5-1 | -4,515 | $32.53 | $147k | 74,158 | Nov 1, 2024 |
| Nov 1, 2024 | MOption exercise Common Stock10b5-1 | +15,485 | $21.10 | $327k | 89,643 | Nov 1, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stock10b5-1 | -15,485 | $32.62 | $505k | 74,158 | Nov 1, 2024 |
| Oct 30, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,515 | $0.00 | $0 | 57,266 | Nov 1, 2024 |
| Nov 1, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,485 | $0.00 | $0 | 41,781 | Nov 1, 2024 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 5Weak | Akero Therapeutics, Inc. | Patrick Lamy Senior VP, Commercial Strategy | $108k 2,000 shares | -6% | |
| 14Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $542k 10,000 shares | -10% | |
| 44Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $80k 1,453 shares | -1% | |
| 39Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $90k 1,633 shares | -2% | |
| 46Moderate | Akero Therapeutics, Inc. | William Richard White Chief Financial Officer | $90k 1,634 shares | -3% | |
| 37Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $62k 1,129 shares | -1% | |
| 37Weak | Akero Therapeutics, Inc. | Patrick Lamy Senior VP, Commercial Strategy | $48k 875 shares | -3% | |
| 36Weak | Akero Therapeutics, Inc. | Scott A. Gangloff Chief Technology Officer | $47k 848 shares | -3% | |
| 55Moderate | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $363k 6,620 shares | -1% | |
| 46Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $135k 2,493 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.